Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

This double-blind, placebo-controlled, full cross-over trial (n=30) will study the effects of psilocybin (10mg/70kg) on brain activity and thought dynamics in healthy volunteers.

Conducted by Johns Hopkins University, this research aims to understand how psilocybin, a psychoactive compound in mushrooms, affects creativity, memory, and brain response to natural stimuli. Using EEG, MRI, and various cognitive tasks, the study seeks to explore the acute psychological and neural effects of psilocybin, potentially aiding in the optimisation of psychedelic medicine and deepening the understanding of consciousness.

Participants, aged 18-75, will receive both psilocybin and placebo in a counter-balanced order, with primary measures including word frequency during free association tasks, memory sensitivity, and EEG alpha band power. The study began on 3rd March 2022, and is expected to complete by 31st December 2024.

Topic Healthy Subjects
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Johns Hopkins University
Johns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.